《股市簡訊》中國復宏漢霖一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理

路透中文

08/14

《股市簡訊》中國<a href="https://laohu8.com/S/02696">復宏漢霖</a>一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理

* 中國復星醫藥2196.HK600196.SS旗下研發生物類似藥的復宏漢霖2696.HK週四早盤一度升4.6%，創2019年上市以來新高，早市收漲0.7%。

* 該公司此前公告稱，眼用注射液HLX04-O用於治療溼性年齡相關性黃斑變性的上市註冊申請獲國家藥品監督管理局藥品審評中心受理。

* 復宏漢霖今年迄今暴漲226.8%，同期恒生指數.HSI大幅上揚27.6%。

* 恒生香港上市生物科技指數.HSHKBIO早盤收高1.1%。（完）

更多股市簡訊請點選CN-CMN-HOT

(發稿徐凱文；審校田鑭沁)

((kaiwen.xu@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559855939"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559855939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559855939?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-14 12:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559855939","market":"us","top_or_hot":-1,"title":"《股市簡訊》中國復宏漢霖一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國<a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理</title></head><body><p>* 中國<a href=\"https://laohu8.com/S/600196\">復星醫藥</a><span>2196.HK</span><span>600196.SS</span>旗下研發<a href=\"https://laohu8.com/S/000504\">生物</a>類似藥的復宏漢霖<span>2696.HK</span>週四早盤一度升4.6%，創2019年上市以來新高，早市收漲0.7%。</p><p>* 該公司此前公告稱，眼用注射液HLX04-O用於治療溼性年齡相關性黃斑變性的上市註冊申請獲國家藥品監督管理局藥品審評中心受理。</p><p>* 復宏漢霖今年迄今暴漲226.8%，同期恒生指數<span>.HSI</span>大幅上揚27.6%。</p><p>* 恒生香港上市生物科技指數<span>.HSHKBIO</span>早盤收高1.1%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 田鑭沁)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市簡訊》中國復宏漢霖一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市簡訊》中國復宏漢霖一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-08-14 12:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國<a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理</title></head><body><p>* 中國<a href=\"https://laohu8.com/S/600196\">復星醫藥</a><span>2196.HK</span><span>600196.SS</span>旗下研發<a href=\"https://laohu8.com/S/000504\">生物</a>類似藥的復宏漢霖<span>2696.HK</span>週四早盤一度升4.6%，創2019年上市以來新高，早市收漲0.7%。</p><p>* 該公司此前公告稱，眼用注射液HLX04-O用於治療溼性年齡相關性黃斑變性的上市註冊申請獲國家藥品監督管理局藥品審評中心受理。</p><p>* 復宏漢霖今年迄今暴漲226.8%，同期恒生指數<span>.HSI</span>大幅上揚27.6%。</p><p>* 恒生香港上市生物科技指數<span>.HSHKBIO</span>早盤收高1.1%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 田鑭沁)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"復宏漢霖","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nL4T3U608K:1","article_id":"2559855939","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559855939","pubTimestamp":1755146177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市簡訊》中國復宏漢霖一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理* 中國復星醫藥2196.HK600196.SS旗下研發生物類似藥的復宏漢霖2696.HK週四早盤一度升4.6%，創2019年上市以來新高，早市收漲0.7%。* 該公司此前公告稱，眼用注射液HLX04-O用於治療濕性年齡相關性黃斑變性的上市註冊申請獲國家藥品監督管理局藥品審評中心受理。* 復宏漢霖今年迄今暴漲226.8%，同期恒生指數.HSI大幅上揚27.6%。* 恒生香港上市生物科技指數.HSHKBIO早盤收高1.1%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","02696":"复宏汉霖","BK0060":"抗癌","BK0239":"医药制造","BK0187":"一线龙头","BK0028":"国家队","BK0096":"民营医院","BK0183":"MSCI概念","BK1161":"生物科技","BK0188":"融资融券","BK1515":"抗疫概念","BK1191":"制药","BK0175":"白马股","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","02196":"复星医药"},"translate_title":"\"Stock Market Newsletter\" China Henlius once rose 4.6% to a new high, and the ophthalmic drug listing application was accepted by the Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9,"02696":0.9},"content_text":"《股市簡訊》中國復宏漢霖一度漲4.6%創新高，眼科藥物上市申請獲藥監局受理* 中國復星醫藥2196.HK600196.SS旗下研發生物類似藥的復宏漢霖2696.HK週四早盤一度升4.6%，創2019年上市以來新高，早市收漲0.7%。* 該公司此前公告稱，眼用注射液HLX04-O用於治療濕性年齡相關性黃斑變性的上市註冊申請獲國家藥品監督管理局藥品審評中心受理。* 復宏漢霖今年迄今暴漲226.8%，同期恒生指數.HSI大幅上揚27.6%。* 恒生香港上市生物科技指數.HSHKBIO早盤收高1.1%。（完）更多股市簡訊請點選CN-CMN-HOT (發稿 徐凱文；審校 田鑭沁) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}